The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.
 
Dong-Wan Kim
Consulting or Advisory Role - Novartis
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Takeda (Inst)
Research Funding - Boehringer Ingelheim (Inst)
 
Kan Chen
Employment - AstraZeneca
 
Ziqiang Cheng
Employment - AstraZeneca
 
Lucy Yin
Employment - AstraZeneca
 
Paul David Martin
Employment - AstraZeneca
 
Zhenfan Yang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - AstraZeneca
 
Haiyi Jiang
Employment - AstraZeneca
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Pfizer
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly
Research Funding - AstraZeneca (Inst)